Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hepatitis

  Free Subscription


21.11.2019

1 Am J Epidemiol
1 Dig Dis Sci
2 Eur J Gastroenterol Hepatol
1 Gastroenterology
2 Gut
2 Hepatology
1 Int J STD AIDS
5 J Hepatol
1 J Immunol
2 J Med Virol
1 J Virol
2 Lancet Gastroenterol Hepatol
1 PLoS One
1 Vaccine
1 Virology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Epidemiol

  1. WILLIAMS-NGUYEN J, Hawes SE, Nance RM, Lindstrom S, et al
    Association of Infection with Chronic Hepatitis C Virus and Myocardial Infarction in People Living with HIV in the United States.
    Am J Epidemiol. 2019 Nov 12. pii: 5622678. doi: 10.1093.
    PubMed     Text format     Abstract available


    Dig Dis Sci

  2. HSU PY, Hsu CT, Yeh ML, Huang CF, et al
    Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
    Dig Dis Sci. 2019 Nov 13. pii: 10.1007/s10620-019-05938.
    PubMed     Text format     Abstract available


    Eur J Gastroenterol Hepatol

  3. SU C, Jin C, Han J, Hu X, et al
    Ultrasonographic assessment of right heart intracardiac mass in patients with hepatitis B virus infection.
    Eur J Gastroenterol Hepatol. 2019 Nov 8. doi: 10.1097/MEG.0000000000001589.
    PubMed     Text format     Abstract available

  4. GOZDAS HT, Ince N
    Elevated mean platelet volume to platelet ratio predicts advanced fibrosis in chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2019 Nov 7. doi: 10.1097/MEG.0000000000001599.
    PubMed     Text format     Abstract available


    Gastroenterology

  5. LAMPERTICO P, Papatheodoridis GV
    IS TENOFOVIR SUPERIOR THAN ENTECAVIR IN REDUCING THE RISK OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B? THE CONTROVERSY CONTINUES.
    Gastroenterology. 2019 Nov 7. pii: S0016-5085(19)41524.
    PubMed     Text format    


    Gut

  6. SHEN DT, Goyal H, Xu HG
    Differences in delta virus hepatitis diagnosis methods and its effect on the hepatitis D prevalence.
    Gut. 2019 Nov 12. pii: gutjnl-2019-320159. doi: 10.1136/gutjnl-2019-320159.
    PubMed     Text format    

  7. MARION O, Lhomme S, Nayrac M, Dubois M, et al
    Hepatitis E virus replication in human intestinal cells.
    Gut. 2019 Nov 14. pii: gutjnl-2019-319004. doi: 10.1136/gutjnl-2019-319004.
    PubMed     Text format     Abstract available


    Hepatology

  8. CAREY I, Gersch J, Wang B, Moigboi C, et al
    Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy.
    Hepatology. 2019 Nov 7. doi: 10.1002/hep.31026.
    PubMed     Text format     Abstract available

  9. CORNBERG M, Lok AS, Terrault NA, Zoulim F, et al
    Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.
    Hepatology. 2019 Nov 12. doi: 10.1002/hep.31030.
    PubMed     Text format     Abstract available


    Int J STD AIDS

  10. FRADE PCR, Raiol NC, da Costa LM, Pinheiro LML, et al
    Factors associated with exposure to hepatitis B virus in female sex workers from the Marajo Archipelago, northern Brazil.
    Int J STD AIDS. 2019;30:1127-1128.
    PubMed     Text format    


    J Hepatol

  11. KIM BK
    Reply to: "Comment on - A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in the Republic of Korea".
    J Hepatol. 2019 Nov 11. pii: S0168-8278(19)30614.
    PubMed     Text format    

  12. GILL US, McCarthy NE
    CD4 T cells in hepatitis B virus: "You don't have to be cytotoxic to work here and help".
    J Hepatol. 2019 Nov 7. pii: S0168-8278(19)30610.
    PubMed     Text format    

  13. CORNBERG M, Suk-Fong Lok A, Terrault NA, Zoulim F, et al
    Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.
    J Hepatol. 2019 Nov 9. pii: S0168-8278(19)30671.
    PubMed     Text format     Abstract available

  14. YU Y, Zhang J, Zhang B, Gao J, et al
    Comment on - A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in the Republic of Korea.
    J Hepatol. 2019 Nov 13. pii: S0168-8278(19)30593.
    PubMed     Text format    

  15. SHIHA G, Soliman R, Mikhail NN, Easterbrook P, et al
    Educate, Test and Treat Model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
    J Hepatol. 2019 Nov 14. pii: S0168-8278(19)30672.
    PubMed     Text format     Abstract available


    J Immunol

  16. DHANDA AD, Williams EL, Yates E, Lait PJP, et al
    Intermediate Monocytes in Acute Alcoholic Hepatitis Are Functionally Activated and Induce IL-17 Expression in CD4(+) T Cells.
    J Immunol. 2019 Nov 13. pii: jimmunol.1800742. doi: 10.4049/jimmunol.1800742.
    PubMed     Text format     Abstract available


    J Med Virol

  17. SHEN S, Lai-Hung Wong G, Kuang Z, van Campenhout MJH, et al
    Development and validation of a model for hepatitis B e Antigen seroconversion in entecavir-treated chronic hepatitis B patients.
    J Med Virol. 2019 Nov 14. doi: 10.1002/jmv.25628.
    PubMed     Text format     Abstract available

  18. LI N, Fan X, Wang X, Zhang X, et al
    Genetic association of polymorphisms at intergenic region between PRDM1 and ATG5 with hepatitis B virus infection in Han Chinese patients.
    J Med Virol. 2019 Nov 15. doi: 10.1002/jmv.25629.
    PubMed     Text format     Abstract available


    J Virol

  19. SINGH D, Soni S, Khan S, Sarangi AN, et al
    Genome-wide mutagenesis of hepatitis C virus reveals genome ability to overcome detrimental mutations.
    J Virol. 2019 Nov 13. pii: JVI.01327-19. doi: 10.1128/JVI.01327.
    PubMed     Text format     Abstract available


    Lancet Gastroenterol Hepatol

  20. SONNEVELD MJ
    Core inhibitor therapy for chronic hepatitis B.
    Lancet Gastroenterol Hepatol. 2019 Nov 8. pii: S2468-1253(19)30325.
    PubMed     Text format    

  21. YUEN MF, Agarwal K, Gane EJ, Schwabe C, et al
    Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
    Lancet Gastroenterol Hepatol. 2019 Nov 8. pii: S2468-1253(19)30346.
    PubMed     Text format     Abstract available


    PLoS One

  22. MANUEL SOUSA J, Vergara M, Pulido F, Sanchez Antolin G, et al
    Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r +/- dasabuvir +/- ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
    PLoS One. 2019;14:e0225061.
    PubMed     Text format     Abstract available


    Vaccine

  23. XU WB, Li Y, Li D, Fang Y, et al
    Investigation and analysis of antibody levels of hepatitis A among children before and after implementing the Expanded National Immunization Program in China.
    Vaccine. 2019 Nov 14. pii: S0264-410X(19)31475.
    PubMed     Text format     Abstract available


    Virology

  24. WANG F, Shen F, Wang Y, Li Z, et al
    Residues Asn118 and Glu119 of hepatitis B virus X protein are critical for HBx-mediated inhibition of RIG-I-MAVS signaling.
    Virology. 2019;539:92-103.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: